Gaurav D. Shah
Directeur Général chez ROCKET PHARMACEUTICALS, INC.
Fortune : 24 M $ au 31/05/2024
Postes actifs de Gaurav D. Shah
Sociétés | Poste | Début | Fin |
---|---|---|---|
ROCKET PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 04/01/2018 | - |
Directeur Général | 04/01/2018 | - | |
President | 04/01/2018 | - | |
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Directeur/Membre du Conseil | 01/09/2015 | - |
Directeur Général | 01/09/2015 | - | |
President | 01/09/2015 | - | |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Président | 18/10/2022 | - |
Historique de carrière de Gaurav D. Shah
Anciens postes connus de Gaurav D. Shah
Sociétés | Poste | Début | Fin |
---|---|---|---|
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | 01/01/2011 | 01/09/2015 |
The Trustees of Columbia University in The City of New York | Corporate Officer/Principal | 01/01/2009 | 01/12/2011 |
ELI LILLY AND COMPANY | Directeur Technique/Scientifique/R&D | 01/01/2010 | 01/01/2011 |
TOURMALINE BIO, INC. | Directeur/Membre du Conseil | 01/12/2020 | - |
Independent Dir/Board Member | 01/12/2020 | - |
Formation de Gaurav D. Shah
The Trustees of Columbia University in The City of New York | Doctorate Degree |
Harvard College | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Suisse | 2 |
Opérationnelle
Director/Board Member | 3 |
Chief Executive Officer | 2 |
President | 2 |
Sectorielle
Health Technology | 7 |
Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 2 |
---|---|
ROCKET PHARMACEUTICALS, INC. | Health Technology |
ELI LILLY AND COMPANY | Health Technology |
Entreprise privées | 4 |
---|---|
Rocket Pharmaceuticals Ltd.
Rocket Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Rocket Pharmaceuticals Ltd. operates as a biotechnology company which focuses on developing gene therapy treatment for undertreated diseases. The firm’s pipeline includes Fanconi Anemia, Pyruvate Kinase Deficiency, Leukocyte Adhesion Deficiency-1 and Infantile Malignant Osteopetrosis. It also develops an AAV-based therapy program for an undisclosed rare pediatric disease. The company is headquartered in New York, NY. | Health Technology |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
Talaris Therapeutics, Inc.
Talaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Talaris Therapeutics, Inc. is a late-clinical stage cell therapy company, which engages in the development of allogeneic hematopoietic stem cell transplantation. The company was founded by Suzanne Ildstad on February 15, 2002 and is headquartered in Wellesley, MA. | Health Technology |
Anjarium Biosciences AG
Anjarium Biosciences AG BiotechnologyHealth Technology Anjarium Biosciences AG is a Swiss company that focuses on creating a new class of non-viral gene therapies to tackle genetic diseases throughout a patient's lifetime. The company is based in Schlieren, Switzerland. The company's versatile platform leverages breakthrough science and expertise at the interface of genetic medicine, synthetic biology, and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Anjarium's investors include leading international and strategic investors such as Abingworth, Gimv, Omega Funds, Pfizer Ventures, and Surveyor Capital. The company was founded by Joël de Beer, and Stephen Yoo has been the CEO of the company since 2022. | Health Technology |
- Bourse
- Insiders
- Gaurav D. Shah
- Expérience